Risk-based monitoring, usually shortened to RBM, is a clinical-trial oversight strategy that focuses monitoring effort on the data and processes most likely to affect participant safety, rights, wellbeing, or study reliability. Instead of assuming every site and every record needs the same amount of scrutiny, RBM prioritizes the parts of a study where errors or drift would matter most.
Why It Matters In AI
AI makes RBM more practical by helping teams detect unusual site behavior, delayed visits, device-sync failures, missing data, protocol deviations, and changing enrollment or adherence patterns faster than manual review alone. That is why RBM often overlaps with anomaly detection, time series forecasting, workflow orchestration, and modern centralized analytics.
What Good Use Looks Like
Strong RBM does not mean monitoring less carelessly. It means monitoring more intentionally. Good implementations define critical data and processes early, establish thresholds and escalation rules, track key risk indicators over time, and route unusual signals to the right reviewer with clear accountability. AI can help score and prioritize, but human monitors, investigators, and quality teams still decide what action to take.
Where You See It
RBM is most visible in multicenter, hybrid, and decentralized trials where teams need a central view across sites, devices, source systems, and participant workflows. It is especially useful when remote data capture increases the volume and speed of signals that need to be triaged.
Related Yenra articles: Clinical Trial Management, Automated Legal Compliance Monitoring, Patient Outcome Prediction, Precision Oncology and Targeted Therapies, and Personalized Medicine.
Related concepts: Anomaly Detection, Workflow Orchestration, Continuous Controls Monitoring (CCM), Electronic Health Record (EHR), Real-World Evidence (RWE), Digital Biomarker, Time Series Forecasting, and Document AI.